SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARADIGM CORP. ARDM

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Tadsamillionaire8/4/2006 10:22:36 PM
   of 255
 
Aradigm Corporation Second Quarter 2006 Earnings and Conference Call Notification
Aradigm Corporation (NASDAQ: ARDM) will announce its second quarter 2006 financial results on Thursday, August 10, 2006, after the close of the U.S. financial markets. The Company will host a live webcast and conference call at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time that same day.

Date: Thursday, August 10, 2006
Time: 4:30 p.m. Eastern, 1:30 p.m. Pacific
Internet: The live webcast can be accessed at www.aradigm.com
Telephone: 1 (877) 788-8790
International callers, dial +1 (706) 679-7281
Passcode: 3423978 or mention Dr. Bryan Lawlis as moderator

For those unable to listen to the live broadcast, a replay will be available under the Investors section of the company website or by dialing 1 (800) 642-1687 (U.S. domestic) or +1 (706) 645-9291 (international) and entering in the conference ID # 3423978 beginning approximately one hour after the completion of the call.

Aradigm combines its non-invasive delivery systems with novel formulations to create products that enable patients to comfortably self-administer biopharmaceuticals and small molecule drugs. The company's advanced AERx® pulmonary and Intraject® needle-free delivery technologies offer rapid delivery solutions for liquid drug formulations. Current development programs and priorities focus on the development of specific products, including partnered and self-initiated programs in the areas of respiratory conditions, neurological disorders, heart disorders, and smoking cessation. In addition, Aradigm and its partner, Novo Nordisk, are in Phase 3 clinical trials of the AERx Diabetes Management System for the treatment of Type 1 and Type 2 diabetes. More information about Aradigm can be found at www.aradigm.com.

Aradigm, AERx and Intraject are registered trademarks of Aradigm.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext